Vyriad raises $25M final tranche — funds VV‑169 first‑in‑human push

Vyriad closed a $25 million final tranche of its series B financing, bringing total Series B proceeds to $85 million to fund first‑in‑human testing of VV‑169, an in vivo CAR T candidate targeting relapsed or refractory multiple myeloma. The financing will support IND‑enabling activities and initial clinical operations for VV‑169. Vyriad’s in vivo CAR T approach aims to simplify manufacturing and broaden patient access compared with ex vivo CAR T therapies. Investors and clinical partners will watch early safety and efficacy readouts to assess whether in vivo CAR T can deliver scalable, off‑the‑shelf benefits in hematologic malignancies.